MAPT and Alzheimer disease: Thanks to their diagnostic accuracy, CSF biomarkers are also used in the clinical diagnosis of AD, and include markers for fibrillar neurodegeneration (such as total tau protein (Tau) and tau protein phosphorylated at threonine 181 (181p-tau)) and the deposition of β-amyloid1-42 [Aβ1-42].